John Oyler Sells 30,520 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock
John Oyler Sells 30,520 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock
BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) CEO John Oyler sold 30,520 shares of the company's stock in a transaction on Tuesday, September 20th. The stock was sold at an average price of $153.50, for a total value of $4,684,820.00. Following the sale, the chief executive officer now owns 2,070,913 shares of the company's stock, valued at $317,885,145.50. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
百济神州(纳斯达克代码：BGNE-GET Rating)首席执行官约翰·奥勒在9月20日(星期二)的一次交易中出售了30,520股票。这只股票的平均售价为153.50美元，总价值为4,684,820.00美元。出售后，这位首席执行官现在持有该公司2,070,913股股票，价值317,885,145.50美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可通过此超链接.
BeiGene Trading Down 3.7 %
百济神州股价下跌3.7%
BeiGene stock opened at $138.64 on Friday. The stock has a 50-day moving average of $173.46 and a two-hundred day moving average of $167.46. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.35 and a current ratio of 4.54. BeiGene, Ltd. has a one year low of $118.18 and a one year high of $392.30. The stock has a market cap of $14.37 billion, a PE ratio of -6.79 and a beta of 0.65.
百济神州的股票周五开盘报138.64美元。该股的50日移动均线切入位在173.46美元，200日移动均线切入位在167.46美元。该公司的负债权益比率为0.03，速动比率为4.35，流动比率为4.54。百济神州股份有限公司的一年低点为118.18美元，一年高点为392.30美元。该股市值为143.7亿美元，市盈率为-6.79，贝塔系数为0.65。
BeiGene (NASDAQ:BGNE – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported ($5.56) EPS for the quarter, missing analysts' consensus estimates of ($4.23) by ($1.33). BeiGene had a negative net margin of 187.65% and a negative return on equity of 38.58%. The business had revenue of $341.57 million during the quarter, compared to analysts' expectations of $297.28 million. On average, research analysts anticipate that BeiGene, Ltd. will post -17.02 EPS for the current fiscal year.
百济神州(纳斯达克代码：BGNE-GET Rating)最近一次发布季度收益报告是在8月4日星期四。该公司公布本季度每股收益为5.56美元，低于分析师普遍预期的4.23美元和1.33美元。百济神州的净利润率为负187.65%，净资产回报率为负38.58%。该业务本季度营收为3.4157亿美元，高于分析师预期的2.9728亿美元。研究分析师平均预计，百济神州有限公司本财年每股收益将达到17.02欧元。
Analyst Ratings Changes
分析师评级发生变化
Institutional Investors Weigh In On BeiGene
机构投资者看好百济神州
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Koshinski Asset Management Inc. increased its holdings in shares of BeiGene by 139.6% in the first quarter. Koshinski Asset Management Inc. now owns 242 shares of the company's stock valued at $46,000 after purchasing an additional 141 shares during the period. Steward Partners Investment Advisory LLC acquired a new position in shares of BeiGene in the second quarter valued at about $65,000. Advisors Asset Management Inc. increased its holdings in shares of BeiGene by 26.7% in the first quarter. Advisors Asset Management Inc. now owns 1,244 shares of the company's stock valued at $235,000 after purchasing an additional 262 shares during the period. Desjardins Global Asset Management Inc. increased its holdings in shares of BeiGene by 7.6% in the second quarter. Desjardins Global Asset Management Inc. now owns 1,523 shares of the company's stock valued at $246,000 after purchasing an additional 107 shares during the period. Finally, Laurel Wealth Advisors Inc. acquired a new position in shares of BeiGene in the fourth quarter valued at about $249,000. 51.77% of the stock is currently owned by hedge funds and other institutional investors.
一些对冲基金和其他机构投资者最近增持或减持了该业务的股份。今年第一季度，科辛斯基资产管理公司增持了139.6%的百济神州股票。Koshinski Asset Management Inc.在此期间又购买了141股，目前持有242股该公司股票，价值4.6万美元。Steward Partners Investment Consulting LLC在第二季度收购了百济神州的新股票头寸，价值约65,000美元。Advisors Asset Management Inc.今年第一季度增持了26.7%的百济神州股票。Advisors Asset Management Inc.在此期间又购买了262股，现在拥有1,244股该公司股票，价值23.5万美元。Desjardins Global Asset Management Inc.在第二季度增持了7.6%的百济神州股票。Desjardins Global Asset Management Inc.在此期间又购买了107股，目前持有1,523股该公司股票，价值24.6万美元。最后，Laurel Wealth Advisors Inc.在第四季度增持了价值约249,000美元的百济神州股票。51.77%的股票目前由对冲基金和其他机构投资者持有。
About BeiGene
关于百济神州
(Get Rating)
(获取评级)
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).
百济神州是一家生物技术公司，专注于在全球范围内发现、开发、制造各种药物并将其商业化。其产品包括用于治疗复发/难治性(R/R)套细胞淋巴瘤的BRUKINSA；用于治疗R/R经典霍奇金淋巴瘤的Tislelizumab；用于治疗多发性骨髓瘤的Revlimid；用于治疗骨髓增生异常综合征、慢性单核细胞白血病和急性髓细胞白血病的VIDAZA；用于治疗骨巨细胞瘤的XGEVA；用于治疗急性淋巴细胞白血病的BLINCETO；用于治疗R/R多发性骨髓瘤的Kyprolis；用于治疗特发性多中心Castleman病的SYLVANT；用于治疗神经母细胞瘤的QARZIBA；用于治疗各种实体肿瘤的Pamiparib；以及用于治疗转移性结直肠癌、肝癌和非小细胞肺癌(NSCLC)的Povcy。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on BeiGene (BGNE)
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- 2 Semiconductor Stocks To Watch For Reversals
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- 免费获取斯托克新闻网关于百济神州的研究报告(BGNE)
- MarketBeat：回顾一周9/19-9/23
- 为什么特斯拉的股票保持弹性？
- 小盘股的裁员是楼市的晴雨表吗？
- 需要关注的2只半导体类股走势逆转
- 好市多盈利后价格疲软是买入的好时机吗？
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.
接受《百济神州日报》的新闻和评级-在下面输入您的电子邮件地址，即可通过MarketBeat.com的免费每日电子邮件时事通讯接收对百济神州及相关公司的最新新闻和分析师评级的每日摘要。
译文内容由第三方软件翻译。